Biodexa Pharmaceuticals Bolsa (NASDAQ: BDRX)

Últimas noticias sobre Biodexa Pharmaceuticals (NASDAQ:BDRX) Bolsa

Biodexa Pharmaceuticals

Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals PLC

BOMBARDIER 6.25% PFD A by Bombardier Inc.

Bombardier Inc

Earnings

News

Morgan Stanley CFO Sharon Yeshaya Sees Investment Banking Activity Increasing Over The Next Quarters; U.S. Presidential Election Will Remove One Of The Key Uncertainties Holding Deals; Private Equity Firms Increasing Demand For IPOs In The U.S. and Europe; Sees Restructuring Activity In Certain Areas Of Commercial Real Estate Reducing Potential Losses; Bank Is Seeing New Deals From Deeper Relationship Between Wealth And Investment Banking Divisions

"In Q3 2024, we expect WiSA to deliver over 200% sequential revenue growth, driven by both WiSA HT and our new WiSA E IP being in production with a multi-national licensee," said Brett Moyer, CEO of WiSA Technologies. "This specific licensee, which is one of the five current WiSA E licensees signed to date, has integrated our WiSA E software into their source device and our WiSA E module in their speakers. Activation of the WiSA E transmit functionality triggers royalty payments back and generates additional revenue from the sale of WiSA E-enabled receiver modules using a Realtek Wi-Fi chip. We expect to build momentum with continued shipments to this customer with additional deployments anticipated in 2025."

Guidance

WISA

WiSA Sees Q3 2024 Revenue $1M-$1.2M Vs $300K QoQ

WIIM

ASE Tech Holding shares are trading higher after UBS upgraded the stock from Neutral to Buy.

RBC Capital analyst Gregory Renza maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Outperform and raises the price target from $30 to $34.

Price Target

Analyst Ratings

EXEL

RBC Capital Maintains Outperform on Exelixis, Raises Price Target to $34

New AI-Ready Platform, AI-Powered Bot Protection, And Expanded DDoS Protection Aim To Lower Cybersecurity Risks And Simplify IT Infrastructure

Biotech

General

PHIO

A10 Networks Unveils Blueprint To Secure AI Applications And Enhance Cyber Resilience With Integrated Solutions

Stifel analyst Stephen Willey maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Hold and raises the price target from $26 to $30.

Stifel Maintains Hold on Exelixis, Raises Price Target to $30

Phio Pharmaceuticals To Present Data On INSTAYL Compound PH-894 At ASGCT's 2024 Cancer Conference; PH-894 Shows Potent Silencing Of BRD4 In NK Cells, Enhances NK Cell Proliferation And Cytotoxicity

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Roth MKM analyst Scott Stember reinstates Advance Auto Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) with a Neutral and announces $40 price target.

Initiation

Roth MKM Reinstates Neutral on Advance Auto Parts, Announces $40 Price Target

Laboratory Corporation Of America Holdings

NOWDiagnostics Partners With Labcorp To Expand Access To First FDA-Authorized OTC Syphilis Test In The U.S.; First To Know Syphilis Test To Be Available In Clinical And Hospital Settings By Late 2024, With Direct Patient Access Via Labcorp OnDemand In 2025

VS: 489% &#x7C; <a href="https://www.benzinga.com//node/41354474">Versus Systems shares are trading higher after the company announced a $2.5 million investment and licensing agreement with ASPIS.</a>
&nbsp;
NVAX: -32% &#x7C; <a href="https://www.benzinga.com//node/41355032">Novavax shares are trading lower after the FDA placed a clinical hold on the company's investigational new drug application for its COVID-19-influenza combination and standalone influenza vaccine candidates.</a>
&nbsp;
BDRX: 245% &#x7C; <a href="https://www.benzinga.com//node/41354484">Biodexa Pharmaceuticals shares are trading higher after the company announced it successfully appealed Nasdaq's delisting decision and was granted a time extension to demonstrate compliance with its listing rule.</a>

Movers

Trading Ideas

BDRX

NVAX

Market-Moving News for October 16th

Roth MKM analyst Scott Stember reinstates AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) with a Buy and announces $3634 price target.

Roth MKM Reinstates Buy on AutoZone, Announces $3634 Price Target

Alaska Airlines Enhances Mileage Plan For 2025 With New Perks, Faster Elite Status Earning, And Expanded Options For Earning And Redeeming Miles; Single Loyalty Program Coming As Alaska And Hawaiian Airlines Merge

ULTA

Ulta Beauty shares are trading lower after the company provided long-term business strategy plans and reaffirmed its F24 guidance.

A high-stakes power struggle has erupted between Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and activist investor Starboard Value, with Wall Street&#8217;s dealmaker, Alan Schwartz, and his firm, Guggenheim Partners, <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41199793/amid-pfizers-struggles-with-declining-demand-for-covid-19-treatments-activist-investor-starboard" rel="noreferrer noopener">caught in the crossfire</a>.
The activist investor had built a $1 billion&nbsp;stake&nbsp;in the U.S. drug maker. The tension peaked when Pfizer&#8217;s former CEO Ian Read and former CFO Frank D&#8217;Amelio, who initially supported Starboard&#8217;s campaign against Pfizer&#8217;s current CEO Albert Bourla, unexpectedly <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41264265/former-pfizer-executives-ian-read-and-frank-damelio-support-albert-bourlas-leadership-amid-starb" rel="noreferrer noopener">reversed their stance</a>.
Read and D&#8217;Amelio issued a statement expressing full support for Bourla and the board, though this sudden shift in allegiance left insiders puzzled.
Even more surprising was that the statement was released through Guggenheim, a firm that has enjoyed a close relationship with Pfizer and has earned approximately $172 million in advisory fees since 2011, most recently $48 million from the&nbsp;Seagen deal.
Speculation surrounds the reversal, with Jeff Smith, CEO of Starboard, claiming Pfizer pressured the ex-executives with potential legal consequences <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41274121/whats-going-on-with-pfizer-stock-on-thursday" rel="noreferrer noopener">and bonus clawbacks</a>.
Despite not playing an official role in the Starboard-Pfizer dispute, Guggenheim finds itself entangled in one of Wall Street&#8217;s most contentious activist campaigns.
The Financial Times <a target="_blank" href="https://www.ft.com/content/1546d1e6-3bd6-43d8-b17a-919308096ef0" rel="noreferrer noopener">notes</a> that Pfizer has since turned to rival boutique firm PJT Partners to lead its defense, distancing itself from its long-time advisor in this high-profile clash.
Starboard&#8217;s frustration stems from Pfizer&#8217;s declining performance since its COVID-19 vaccine windfall. The company has faced criticism for a series of costly acquisitions, including its $43 billion <a target="_blank" href="https://www.benzinga.com/general/biotech/23/12/36198526/pfizer-clears-required-regulatory-hurdles-to-complete-43b-seagen-acquisition" rel="noreferrer noopener">purchase of </a><a target="_blank" href="https://www.benzinga.com/general/biotech/23/12/36198526/pfizer-clears-required-regulatory-hurdles-to-complete-43b-seagen-acquisition" rel="noreferrer noopener">Seagen</a>.
The FT report highlights that Starboard <a target="_blank" href="https://www.ft.com/content/0f3e13bd-ba02-47a6-9261-1e49d19d6528" rel="noreferrer noopener">argues</a> that these moves, along with poor capital allocation, have contributed to Pfizer&#8217;s stock dropping over 50% from its pandemic peak. The activist investor will likely push for significant changes, possibly including a leadership overhaul or further divestitures.
With Pfizer&#8217;s stagnant revenue growth and limited options for quick fixes, Starboard&#8217;s path to reshaping the company remains uncertain.
Pfizer has already implemented cost-cutting measures and sold off divisions, leaving few levers for change.
Price Action: PFE stock is up 0.31% at $29.53 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41310468/fda-approves-pfizers-second-hemophilia-drug-with-six-months" target="_blank" rel="noreferrer noopener">FDA Approves Pfizer&#8217;s Second Hemophilia Drug Within Six Months</a></li>
</ul>
Photo via Shutterstock

Large Cap

Health Care

Guggenheim's Longstanding Pfizer Ties Tested Amid Starboard Battle

Roth MKM analyst Scott Stember reinstates O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) with a Buy and announces $1337 price target.

ORLY

Roth MKM Reinstates Buy on O'Reilly Automotive, Announces $1337 Price Target

TD Cowen analyst Krish Sankar maintains Silvaco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) with a Buy and lowers the price target from $23 to $20.

SVCO

TD Cowen Maintains Buy on Silvaco Group, Lowers Price Target to $20

U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) shares are<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener"> trading higher on Wednesday.</a>
The company reported <a target="_blank" href="https://s203.q4cdn.com/711684571/files/doc_financials/2024/q3/Press-Release-3Q24.pdf" rel="noreferrer noopener">third-quarter</a> adjusted earnings per share of $1.03, beating the analyst <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41353142/u-s-bancorp-reports-third-quarter-2024-results" rel="noreferrer noopener">consensus estimate of 99 cents.</a>
Quarterly revenues of $6.864 billion missed the analyst consensus estimate of $6.895 billion.
The third quarter included $119 million of net losses on investment securities sales ($89 million net-of-tax), which was largely offset by lower income tax expenses, which reflected certain tax settlements.
&#8220;Our expense levels decreased year-over-year which supported modest positive operating leverage, excluding net securities losses and prior year notable items,&#8221; said Andy Cecere, Chairman and CEO, U.S. Bancorp.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41255250/banks-gear-up-for-earnings-season-15-top-stock-picks-including-citigroup-morgan-stanley-and-truist" rel="noreferrer noopener">Banks Gear Up For Earnings Season: 15 Top Stock Picks Including Citigroup, Morgan Stanley, And Truist</a>
Net interest income fell 2.4% to $4.135 billion in the quarter under review, due to the impact of higher interest rates on deposit mix and pricing. Third quarter noninterest income of $2.698 billion, down 2.4% year over year.
The provision for credit losses increased by $42 million (8.2%) compared with the third quarter of 2023, largely due to higher losses on credit card, commercial, and commercial real estate loans.
&#8220;Credit quality results were in line with expectations, and we continue to increase our capital position, ending the quarter with a CET1 capital ratio of 10.5%,&#8221; Cecere added. The CET1 capital ratio of 10.5% on September 30 was up from 10.3% on June 30.
The average total deposits for the third quarter were $3.5 billion, which was 0.7% lower year over year.
Price Action: USB shares are trading higher by 1.91% to $47.90 premarket at last check Wednesday.
Photo by JHVEPhoto via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41249837/s-p-500-earnings-season-kicks-off-why-analysts-call-this-quarter-a-stock-pickers-paradise" target="_blank" rel="noreferrer noopener">S&amp;P 500 Earnings Season Kicks Off: Why Analysts Call This Quarter ‘A Stock Picker's Paradise'</a></li>
</ul>

Equities

Markets

U.S. Bancorp Q3 Earnings: EPS Beat, Revenue Miss, Rising Credit Loss Provisions & More

<a href="https://www.bloomberg.com/news/articles/2024-10-16/blackrock-in-talks-with-ambani-for-india-private-credit-venture" title="https://www.bloomberg.com/news/articles/2024-10-16/blackrock-in-talks-with-ambani-for-india-private-credit-venture">https://www.bloomberg.com/news/articles/2024-10-16/blackrock-in-talks-with-ambani-for-india-private-credit-venture</a>

'BlackRock in Talks With Ambani for India Private Credit Venture' - Bloomberg

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) are surging, with the former benefitting from social media chatter about Elon Musk <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41220500/elon-musk-says-potential-doge-department-under-a-trump-administration-will-be-a-garbage-co">heading a &#8220;D.O.G.E&#8221; department. </a>
What Happened: Dogecoin, Shiba Inu and Dogecoin-themed cryptocurrencies have performed exceptionally well over the past 24 hours:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price</td>
<td>Market cap</td>
<td>  24-hour trend</td>
<td>7-day trend</td>
</tr>
<tr>
<td>Dogecoin </td>
<td>$0.1256</td>
<td>$18.386B</td>
<td> +11.2%</td>
<td>+15.1%</td>
</tr>
<tr>
<td>Shiba Inu </td>
<td>$0.00001875</td>
<td>$11.04B</td>
<td> +5.2%</td>
<td>+7.2%</td>
</tr>
<tr>
<td>Department Of Government Efficiency (D.O.G.E)</td>
<td>$0.026</td>
<td>$25.68M</td>
<td>+122.4%</td>
<td>+152.4%</td>
</tr>
</tbody>
</table>
</figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41313977/dogecoins-on-chain-data-chart-patterns-flash-bullish-signals-this-top-analyst-thinks-its-a">Dogecoin&#8217;s On-Chain Data, Chart Patterns Flash Bullish Signals: This Top Analyst Thinks It&#8217;s A &#8216;Buy&#8217;</a>
Trader Notes: Crypto analysts are speculating on the potential impact of <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41313912/harris-or-trump-bitcoin-to-be-in-win-win-position-irrespective-of-who-wins-the-white-house">a Trump victory</a> in the upcoming U.S. presidential election on certain cryptocurrencies, particularly those associated with the &#8220;DOGE&#8221; narrative.
Andrew Kang <a href="https://x.com/Rewkang/status/1846231275847454786">suggests</a> that owning Dogecoin and other meme coins could be &#8220;one of the most interesting ways to express a &#8216;Trump Victory&#8217; trade.&#8221; He points to the increased likelihood of a <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39334602/arthur-hayes-raoul-pal-predict-dogecoin-etf-if-people-wait-in-line-for-luxury-brands-they-">Dogecoin ETF</a> and the potential creation of a<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40780511/dogecoin-surges-8-as-elon-musk-jokes-doge-will-be-the-official-mascot-of-department-of-gov"> Department of Government Efficiency (DOGE)</a> under a Trump administration, which could keep the cryptocurrency in the headlines.
Supporting this view, analyst Unipcs <a href="https://x.com/theunipcs/status/1846474366684438605">highlights</a> the recent performance of DOGE-related assets, stating, &#8220;it&#8217;s hard not to be bullish on both doges if you really think Trump is going to win.&#8221; 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Statistics: IntoTheBlock data shows Dogecoin's large transaction volume increasing by 4.6% and daily active addresses falling by 1.5%. Transactions greater than $100,000 are up from&nbsp; 317 to 394 in a single day.
Shiba Inu's large transaction volume is down by 24.5% and daily active addresses are up by 17.2%. Shiba Inu has burned around 3 million SHIB coins from its ecosystem over the past 24 hours.
Community News: The official Dogecoin account picked up on a Shiba Inu-themed easter egg in Tesla&#8217;s Robotaxi presentation:
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Hey <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@elonmusk</a> is that a Shiba Inur taxi? <a href="https://t.co/ihfktgc4ds">pic.twitter.com/ihfktgc4ds</a>
&mdash; Dogecoin (@dogecoin) <a href="https://twitter.com/dogecoin/status/1844591727656448375?ref_src=twsrc%5Etfw">October 11, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Dogecoin-themed account Doge Designer <a href="https://x.com/cb_doge/status/1844595234316943841">noted</a> the same, wondering whether Musk would really allow purchases with Dogecoin in the future.
What&#8217;s Next: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41312634/dogecoin-killer-shiba-inu-incinerates-277m-coins-in-1-transaction-watch-these-levels-for-a">&#8216;Dogecoin Killer&#8217; Shiba Inu Incinerates 277M Coins In 1 Transaction: Watch These Levels For A Bullish Rally</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$SHIB

Dogecoin Rockets Up 10%, Shiba Inu Spikes 5%: What Is Going On?

Biodexa gets delisting letter from Nasdaq

Biodexa Pharmaceuticals (BDRX) has released an update. Biodexa Pharmaceuticals PLC faces potential delisting from the Nasdaq Capital Market due to ...

Biodexa Pharmaceuticals Confronts Nasdaq Delisting

Biodexa Pharmaceuticals (BDRX) has released an update. Biodexa Pharmaceuticals PLC has successfully made a $3 million payment, unlocking the remain...

Biodexa Pharmaceuticals Advances FAP Treatment

Biodexa Pharmaceuticals announces ADR ratio change

Biodexa Pharmaceuticals (BDRX) has released an update. Biodexa Pharmaceuticals has announced significant operational and financial achievements for...

Biodexa Pharmaceuticals Reports Promising H1 2024 Results

Biodexa Pharmaceuticals GAAP EPS of -0.10p

Biodexa Pharmaceuticals (BDRX) has released an update. Biodexa Pharmaceuticals reports promising interim results in their Phase 1 study of MTX110 f...

Biodexa's MTX110 Shows Promise in Brain Cancer Study

Biodexa reports updated Phase 1 data from glioblastoma study

Biodexa announces successful appeal of Nasdaq delisting

Biodexa Pharmaceuticals (BDRX) has released an update. Biodexa Pharmaceuticals has successfully appealed a Nasdaq delisting decision, securing an e...

Biodexa Pharmaceuticals Secures Nasdaq Compliance Extension

Screenshot 2024-07-10 at 9.15.35 PM

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa In Treatment Of Precancerous Polyps In The GI Tract – Now 12-Month Data

Screenshot 2024-06-03 at 5.21.04 PM

Promising Phase 2 Results For Biodexa&#39;s eRapa™ Indicates Hope For FAP Patients Who Otherwise Have A 100% Lifetime Risk Of Colorectal Cancer

Screenshot 2024-05-08 at 7.48.00 PM

Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition

Untitled design - 2024-03-28T172702.605

Biodexa&#39;s MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

Redington 2_29

PowerShares Dynamic Financial Sector Portfolio

Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone

Press Releases

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data

Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada

Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

Receipt of Nasdaq Delisting Determination - Plans to Appeal

Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of  $17.0MM CPRIT Grant

ADR Ratio Change

Interim results for the six months ended June 30, 2024

Biodexa Provides Update on Progression Free and Overall Survival in  Phase 1 Study of MTX110 in Recurrent Glioblastoma

Biodexa Announces Successful Appeal of Nasdaq Delisting

Aileron Therapeutics, Inc. - Common Stock

Aileron Therapeutics

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

Cidara Therapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Chimerix

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Citius Oncology

Cue Biopharma

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Immuneering Corporation - Class A Common Stock

Immuneering

IO Biotech

Kezar Life Sciences

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

Metagenomi

Ovid Therapeutics

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

PMV Pharma

RAPT Therapeutics

Serina Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Spero Therapeutics

Shattuck Labs

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

Ladenburg Thalmann

Biodexa Pharmaceuticals shares are trading higher after the company announced it successfully appealed Nasdaq's delisting decision and was granted a time extension to demonstrate compliance with its listing rule.

Comments

Biodexa Pharmaceuticals

Noticias

Últimas noticias sobre Biodexa Pharmaceuticals (NASDAQ:BDRX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL